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RESEARCH ARTICLE

Open Access

Spontaneous feline mammary intraepithelial
lesions as a model for human estrogen
receptor- and progesterone receptor-negative
breast lesions
Giovanni P Burrai1,2, Sulma I Mohammed2,5,6, Margaret A Miller2, Vincenzo Marras3, Salvatore Pirino1,
Maria F Addis4, Sergio Uzzau4, Elisabetta Antuofermo1*

Abstract
Background: Breast cancer is the most frequently diagnosed cancer in women. Intraepithelial lesions (IELs), such as
usual ductal hyperplasia (UH), atypical ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS) are risk factors
that predict a woman’s chance of developing invasive breast cancer. Therefore, a comparative study that
establishes an animal model of pre-invasive lesions is needed for the development of preventative measures and
effective treatment for both mammary IELs and tumors. The purpose of this study was to characterize the
histologic and molecular features of feline mammary IELs and compare them with those in women.
Methods: Formalin-fixed, paraffin-embedded specimens (n = 205) from 203 female cats with clinical mammary
disease were retrieved from the archives of the Purdue University Animal Disease Diagnostic Laboratory and
Veterinary Teaching Hospital (West Lafayette, IN), and the Department of Pathology and Veterinary Clinic, School of
Veterinary Medicine (Sassari, Italy). Histologic sections, stained with hematoxylin and eosin (HE), were evaluated for
the presence of IELs in tissue adjacent to excised mammary tumors. Lesions were compared to those of humans.
Immunohistochemistry for estrogen receptor (ER-alpha), progesterone receptor (PR), human epidermal growth
factor receptor 2 (HER-2/neu) and Ki-67 was performed in IELs and adjacent tumor tissues.
Results: Intraepithelial lesions were found in 57 of 203 (28%) feline mammary specimens and were categorized as
UH (27%), ADH (29%), and DCIS (44%). Most IELs with atypia (ADH and DCIS) were associated with mammary
cancer (91%), whereas UH was associated with benign lesions in 53% of cases. Feline IELs were remarkably similar
to human IELs. No ER or PR immunoreactivity was detected in intermediate-grade or high-grade DCIS or their
associated malignant tumors. HER-2 protein overexpression was found in 27% of IELs.
Conclusion: The remarkable similarity of feline mammary IELs to those of humans, with the tendency to lose
hormone receptor expression in atypical IELs, supports the cat as a possible model to study ER- and PR-negative
breast lesions.

Background
Breast cancer is the second leading cause of death in
women in the United States, with about 1,479,350
expected cases in 2009. This accounts for 27% (192,370)
of all new cancer cases among women and 562,340
deaths per annum [1]. With the implementation of
* Correspondence: eantuofermo@uniss.it
1
Department of Pathology and Veterinary Clinic, Faculty of Veterinary
Medicine, Sassari University, Italy

mammographic screening, great progress in early breast
cancer diagnosis has been achieved. Nowadays, many
women are diagnosed with preinvasive intraepithelial
lesions (IELs). Approximately half a million breast IELs
are diagnosed yearly; these include 360,000 cases of usual
hyperplasia (UH), 60,000 of atypical ductal hyperplasia
(ADH) [2], and 57,604 of ductal carcinoma in situ
(DCIS) [1].

© 2010 Burrai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
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Detection and evaluation of IELs are used routinely to
estimate a woman’s risk of developing breast cancer and
to aid physicians in designing optimal therapeutic strategies. It was postulated, based on epidemiological studies,
that the risk for breast cancer ranges from 1.5-2, 4-5,
and 8-10, respectively, for women diagnosed with UH,
ADH, and DCIS [3,4]. Understanding the histopathological and molecular characteristics of the IELs will assist
in elucidating the pathogenesis of breast cancer and
identifying specific therapeutic targets [5]. Several transplantable or chemically induced rodent models have
been developed to study human cancers, including
osteosarcoma, melanoma, bladder and intestinal tumors,
non-Hodgkin lymphoma and mammary tumors [6].
However, these models lack many aspects of human
cancers [7]. An animal model that develops spontaneous
mammary tumors that resemble human breast cancer in
many aspects is needed [8,9].
Feline mammary carcinoma is similar to human breast
cancer in the age of onset, incidence, histopathologic
features, biologic behavior, and pattern of metastasis
[9,10]. The annual incidence of feline mammary neoplasia was estimated at 12.8-25.4 per 100,000 female cats
[11]. About 85% - 93% of feline mammary tumors are
malignant, and there is little breed-associated predilection, except that Siamese cats appear to have a 2-fold
increased risk. Mammary neoplasia has been reported to
occur in cats from 9 months to 23 years of age (mean,
10 to 12 years) [11,12]. Hormonal influences are probably involved in the pathogenesis of feline mammary
neoplasia. Cats that are ovariohysterectomized before 6
months or 1 year of age had 91% and 86% reduction in
risk of developing mammary tumors, respectively, when
compared to intact female cats [13].
These data implicate ovarian hormones in the development of feline mammary tumors [14]. The influence
of hormonal factors is emphasized by Misdorp et al.,
who demonstrated that the regular and prolonged
administration of progestins (used for estrus prevention
in cats) increased the risk of mammary tumor development [15]. The influence of ovarian hormones is also
well-established in humans. Early menarche, before age
12, increases the risk four-fold, as does late menopause
[16].
In humans, ER+ tumors have a better prognosis, and
50-60% of cases tend to respond to hormonal treatments [17,19]. ER+ breast carcinomas are usually
(70-80%) well-differentiated with low expression of proliferation markers [18]. However, 30% of human breast
cancers are ER-negative with a worse prognosis than
ER-positive tumors [19]. Most cats (80%) tend to have
ER-negative, highly aggressive mammary tumors; thus,
they may be particularly suitable as animal models of
human hormone-unresponsive breast cancer [20].
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Human epidermal growth factor receptor 2 (HER-2/
neu) is a cell-membrane receptor tyrosine kinase,
normally involved in the signal transduction pathways
leading to cell growth and differentiation [21]. Approximately 15-20% of breast cancers have amplification of
the HER-2/neu gene or over-expression of its protein
product. HER-2/neu protein over-expression is associated with increased disease recurrence and has been
used to predict patient response to treatment [22]. De
Maria et al. reported that HER-2 gene kinase domain in
cats and humans has 92% homology [23]. HER-2 protein
was highly expressed in feline carcinomas when compared to human breast carcinoma, suggesting its possible role as a prognostic marker [24,25].
To the best of our knowledge, feline mammary IELs
have not been compared with pre-invasive lesions of the
human breast. Thus, this study was undertaken to investigate the prevalence and types of IELs in feline mastectomy specimens and compare them to human breast
IELs, and to determine the expression of ER-a, PR,
HER-2/neu, and Ki67 by immunohistochemistry.

Methods
Tissue samples

Two hundred five formalin-fixed, paraffin-embedded
specimens from 203 female cats with clinical mammary
disease were retrieved from the archives of the Purdue
University Animal Disease Diagnostic Laboratory and
Veterinary Teaching Hospital (West Lafayette, IN) and
the Department of Pathology and Veterinary Clinic,
School of Veterinary Medicine, (Sassari, Italy). Eighty
cats had been spayed before diagnosis; 122 were sexually
intact; the sexual status of 1 cat was unknown. The cats’
age ranged from 0.5-18 years (median, 10 years). Cats of
different breeds were included (82 domestic shorthair,
18 domestic long-hair, 21 European, 10 Siamese, 8 Persian, 4 mixed-breed, 1 Himalayan, 1 Burmese); 58 cats
had no breed designation.
Histology

Histologic sections, stained with hematoxylin and eosin
(HE), were evaluated for the presence of IELs in tissue
adjacent to excised mammary tumors. Lesions were
classified according to criteria for IELs of the human
breast [26,27]. In this study, we focused on the bestcharacterized IELs that arise in the terminal duct-lobular
units; these included UH, ADH and DCIS (low-, intermediate-, and high-grade) [5].
Lesions were classified in consultation with an MD
pathologist (VM) and compared with IELs in women.
Human samples were obtained from the Institute of
Anatomy and Histopathology, Sassari University School
of Medicine. The study protocol was approved by the
Ethical Committee at the University of Sassari. Features
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applicable to usual ductal hyperplasia (UH), also called
epitheliosis, consisted of ducts partially filled by a mixed
population of epithelial and myoepithelial cells that
exceeded 3 or 4 layers in thickness. The diagnosis of
atypical ductal hyperplasia (ADH) was made when the
mixed population of epithelial and myoepithelial cells
had nuclear atypia. In some cases, cords of epithelial
cells formed bridges with irregular fenestrations. In IELs
in which cytologic features of low- or intermediategrade DCIS were observed, but confined to 1 duct
cross-section, the IEL was classified as ADH [26,28].
Ductal carcinoma in situ (DCIS) was diagnosed when
the IEL was composed purely of epithelial cells with
cytologic and architectural atypia. Based on these cytological and architectural characteristics, DCIS was subdivided into 3 categories. Low-grade DCIS was composed
of a proliferation of monomorphic cells with hyperchromatic central nuclei, inconspicuous nucleoli and few
mitotic figures. Intermediate-grade DCIS was distinguished by the lack of the monotonous aspect and moderate nuclear pleomorphism. Finally, high grade DCIS
was composed of pleomorphic atypical cells with large
nuclei, prominent nucleoli, and frequent and/or atypical
mitotic figures. Different patterns were observed (cribriform, papillary, micropapillary, solid, and solid with
comedo-type necrosis). Tumors were classified according to WHO Histological Classification of Mammary
Tumors of the Dogs and Cats [29] and graded according
to a semi-quantitative scheme, originally developed in
humans [30] and applied to feline mammary carcinoma
by Castagnaro [31]. Mammary carcinomas were graded
as well (WDC), moderately (MDC) and poorly differentiated (PDC) carcinoma. Percentage of tubule formation,
mitotic index, cellular and nuclear morphology were
each assigned an individual score from 1 to 3 and then
added, classifying carcinoma as follows: grade I (WDC),
3-5 points; grade II (MDC), 6-7 points; grade III (PDC),
8-9 points.
Immunohistochemistry

Immunohistochemistry was performed using the labeled
streptavidin biotin (LSAB) method. Histologic sections
(5 μm thick) from formalin-fixed, paraffin-embedded
feline mammary tissue with IELs and without IELs (control tissue) were mounted on positively charged Superfrost slides (Fisher Scientific). Tissue sections were
deparaffinized and rehydrated through a series of graded
alcohols. Antigens were retrieved by a high-temperature
heating method (slides were immersed in target retrieval
solution at pH 6 [Dako Cytomation], in a steamer (9095°C) with a 20-minute incubation for all antigens
except for Her-2 neu, for which slides were kept in a
water bath for 40 min at 97°C. Tissues were then
blocked for endogenous peroxidase in 3% hydrogen
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peroxide in water, and for nonspecific binding in PBS
containing 0.25% casein, stabilizing protein and 0.015
mol/L sodium azide (Protein Block Serum-Free, DakoCytomation). Tissues were incubated overnight at 4°C in
the following antisera: ER-a monoclonal mouse antihuman antibody clone NCL-ER-6F11 at 1:40 dilution
(Novocastra Ltd.), progesterone receptor monoclonal
antibody PR 10A9 at 1: 50 dilution (Immunotech, Marselle, France), Ki67 monoclonal mouse anti-human antibody clone MIB-1 at 1:50 dilution (DakoCytomation),
and HER-2/neu polyclonal rabbit anti-human antibody
at 1:100 dilution (DakoCytomation), followed by biotinylated goat anti-mouse or goat anti-rabbit secondary
antibodies (DakoCytomation). The chromogen was 3,3’diaminobenzidine (DakoCytomation). Sections were
counterstained with Mayer’s hematoxylin and
then cover-slipped in 50:50 xylene/Permount (Fisher
Scientific). Negative control slides were treated with isotype-matched IgG serum. Control slides, known to
be positive for each antibody, were incorporated into
each run. Nuclear immunostaining for ER, PR and Ki-67
was evaluated counting a total of 1000 cells in 10 representative fields at high magnification (400×) whereas for
smaller lesions, the entire lesion was considered. The
number of immunopositive cells was expressed as a percentage (mean, median, minimum and maximum values).
The intensity of ER, PR, and Ki67 immunoreactivity
was graded on a scale of 0 to 3, in which 0 = no reactivity, 1 = weak, 2 = moderate, and 3 = strong reactivity.
The over-expression of HER-2/neu was defined as
increased cell membrane reactivity of epithelial cells.
The scoring system according to the HercepTest™ can
be summarized as follows: 0 = no staining or weak and
incomplete membrane staining in less than 10% of the
neoplastic cells; 1+ = incomplete and faint membrane
staining in more than 10% of the neoplastic cells; 2+ =
moderate and complete membrane staining in more
than 10% of the neoplastic cells; 3+ = strong and complete membrane staining in more than 10% of the neoplastic cells. Scores of 0 or 1 were considered negative,
whereas 2 or 3 were considered positive for HER-2/neu
over-expression.
SDS-PAGE and Western Immunoblotting

Protein was extracted from fresh-frozen biopsy specimens from 5 feline mammary carcinomas and 5 normal
mammary glands. Liver was used as a control. Replicate
5-μm-thick slices were cut from frozen tissue blocks.
Five sections of each sample were placed in 2-mL
Eppendorf safe-lock tubes and immersed in Laemmli
buffer for lysis. After incubation on ice for 20 min, tissue lysates were clarified for 10 min at 12,000 × g at
4°C, denatured at 95°C for 5 min, and stored at -80°C
until needed. For electrophoresis, protein extracts from
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fresh-frozen mammary and liver specimens were subjected to SDS-PAGE in 8% polyacrylamide gels according to Laemmli [32]. Electrophoresis was stopped when
the tracker dye reached the end of gels. Proteins were
then stained with Coomassie Brilliant Blue R 250
(Sigma-Aldrich, St. Louis, MO) according to Westermeier [33], decolorized and digitized with an Image Scanner (GE Healthcare).
For western immunoblots, electrophoresed proteins
were transferred to nitrocellulose membranes and
blocked in phosphate buffered saline, 0.05% Tween 20
(PBS-T), plus 5% skim milk for 1 hour to overnight.
The membrane was then incubated with the HER-2/neu
polyclonal rabbit anti-human antibody at 1:1000 dilution
(DakoCytomation) in PBS-T plus 2% skim milk for
2 hours, washed five times with PBS-T, and incubated for
1 h with peroxidase-conjugated goat anti-rabbit secondary antibodies (Sigma-Aldrich) in PBS-T plus 2% skim
milk. After washing the membrane five times with PBST, immunoreactivity was visualized by incubation with a
chemiluminescent peroxidase substrate (Sigma-Aldrich).
Statistical analysis

Differences in IHC expression of ER, PR, Her-2/neu and
Ki67 between types of IELs (e.g., ADH and UH) was
obtained by a standard t-test for two-group comparison.
Correlation between IELs and the adjacent tumors for
ER, PR, HER-2/neu and Ki67 was obtained by simple
regression analysis.

Results
Histology

Sixty-three mammary IELs were identified in mastectomy specimens from 57 (28%) of the 203 female cats; 6
cats had multiple IELs. The lesions were classified as
UH (n = 17, 27%), ADH (n = 18, 29%) and DCIS (n =
28, 44%), and are listed in Table 1, in order of increasing risk for the development of mammary carcinoma, as
described in humans [3,4]. The association between
IELs (UH, ADH, or DCIS) and mammary tumors is also
illustrated. Different morphological patterns were
observed in DCIS: 4 were cribriform (1 low grade,
3 intermediate grade), 9 papillary (2 low grade, 7

intermediate grade), 4 micropapillary (2 low grade, 1
low grade, 1 high grade), 6 solid (1 low grade, 1 intermediate grade, 4 high grade) and 5 were comedo type
DCIS (5 high grade).
Eight of 17 (47%) cases of UH were associated with
malignant tumors, whereas 9 of 17 (53%) cases of UH
were associated with benign lesions. In contrast, 17 of
18 cases ADH were associated with malignant tumors
and only one case of ADH (6%) was associated with a
benign neoplasm. In addition, DCIS, sub-classified as
low, intermediate, and high grade, was associated with
malignant tumors in all except 3 cases. All IELs (UH,
ADH, and DCIS), as well as non-lesional feline mammary gland, were histologically similar to their human
counterparts as depicted in Figures 1 and 2. Of the 205
palpable mammary masses, 168 (82%) were malignant
tumors. In addition, 21/205 (10%) benign tumors, 10/
205 (5%) duct ectasia and 6/205 (3%) cases of fibroadenomatous change were identified. Table 2 lists the different histological patterns and grade of feline malignant
mammary tumors. Six cases of tubulopapillary adenocarcinoma were sub-classified as micropapillary variant
when more than 50% of the tumor had an infiltrating
micropapillary pattern, as described by Seixas [34].
Based on the grading scheme, 14% of the mammary carcinomas were well differentiated; 51%, moderately; and
35%, poorly differentiated.
Immunohistochemistry

Eight of 63 lesions could not be evaluated immunohistochemically either because of suboptimal fixation or lack
of sufficient tissue in the paraffin block. Immunohistochemistry was performed on 55 IELs and associated
tumor tissues, of which 44 were malignant. Twenty normal feline mammary gland, surrounding the 55 lesion,
were also evaluated.
Expression of ER in IELs (Figure 3, A1-A6)

Fifteen of 20 non-neoplastic feline mammary tissue
(75%) expressed strong to moderate ER immunoreactivity in 65% of epithelial cells (mean ± SD: 65 ± 4.81;
median: 64; range: 60 - 76). Immunoreactivity was also
detected in 10 of 16 (62.5%) UH, in which 26% of the
cells had weak to strong immunoreactivity (mean ± SD:

Table 1 Feline mammary IELs (classified by human risk [3,4]) and their association with invasive cancer
Risk

Number of IELs

% of total IELs

No. IELs associated
with malignant tumors

% IELs associated
with malignant tumors

Slight

Ductal hyperplasia n = 17

27%

8/17

47%

Intermediate

Atypical ductal hyperplasia n = 18

29%

17/18

95%

High

Ductal carcinoma in situ n = 28

44%

25/28

89%

6/6

100%

✓ low grade

6

✓ intermediate

11

9/11

82%

✓ high

11

10/11

91%
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Figure 1 Histopathology of normal mammary gland, UH, ADH in woman and cat. Normal secretory mammary gland in woman (A) and cat
(B): the epithelial cells are vacuolated with cytoplasmic accumulation of fat droplets. HE. Bar = 10 μm. Usual ductal hyperplasia (UH) in woman (C)
and cat (D) with typical fenestrated growth pattern. The ducts are lined by monotonous luminal epithelial cells that are cuboidal to columnar, with
hyperchromatic nuclei and rarely prominent nucleoli. Few myoepithelial cells are admixed in the hyperplastic epithelium. HE. Bar = 10 μm. Atypical
ductal hyperplasia (ADH) in woman (E) and cat (F) with micropapillary projection of disorganized epithelial cells and spindle-shaped (myoepithelial)
cells. Epithelial cells are enlarged with round nuclei with coarse chromatin and prominent single nucleoli. HE. Bar = 10 μm.
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Figure 2 Histopathology of low, intermediate, high-grade DCIS in woman and cat. Low-grade ductal carcinoma in situ (DCIS) in woman
(A) and cat (B) with proliferation of monomorphous, small and relatively uniform epithelial cells with moderate and eosinophilic cytoplasm, oval
nuclei, arranged to form regular cribriform spaces. HE. Bar = 10 μm. Intermediate-grade ductal carcinoma in situ (DCIS) in woman (C) and cat (D)
with proliferation of pleomorphic cuboidal cells with moderate eosinophilic cytoplasm, oval to elongate nuclei, and single prominent nucleoli;
micropapillary pattern. Central secretion, necrotic cell debris and periductal inflammatory reaction is depicted in the human intermediate-grade
DCIS. HE. Bar = 10 μm. High-grade comedo ductal carcinoma in situ in woman (E) and cat (F) with solid proliferation of epithelial cells in a
distended duct with central necrosis. Highly pleomorphic cuboidal to oval cells with abundant eosinophilic granular cytoplasm, round vescicular
nuclei and prominent nucleoli. Lymphocytes and plasma cells infiltrate the periductal stroma. Bar = 10 μm.
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Table 2 Feline mammary tumors classified according to Elston and Ellis grading system [31]
Histological pattern

totals

Number of tumors graded as
Well differentiated

Moderately differentiated

Poorly differentiated

(WDC)

(MDC)

(PDC)

Tubulopapillary carcinoma

123

24

76

23

Solid carcinoma

42

0

9

33

Squamous cell carcinoma

3

0

0

3

totals
%

168

24

85

59

14%

51%

35%

Figure 3 Immunohistochemical evaluation of ER-a, PR, Ki-67, HER-2/neu in feline normal mammary gland, UH, ADH and DCIS. Strong
and diffuse nuclear expression of ER-a in non neoplastic feline mammary gland (A1) and in UH (A2). ADH with patchy ER-a expression in
epithelial cells (A3). Low (A4) intermediate (A5) and high grade (A6) DCIS with no ER-a expression. Immunoperoxidase-DAB. Bar = 10 μm. Strong
and multifocal nuclear immunoreactivity of PR in non neoplastic feline mammary gland (B1). Lack of PR immunoreactivity in UH (B2), ADH (B3),
low (B4), intermediate (B5), and high grade (B6) DCIS. Immunoperoxidase-DAB. Bar = 10 μm. Few and strong Ki-67 nuclear immunoreactivity in
non neoplastic feline mammary gland (C1). UH displaying strong and scattered Ki-67 immunolabeling (C2). ADH with widespread and strong
Ki-67 expression (C3). DCIS low (C4), intermediate (C5), and high grade (C6) with strong and multifocal Ki-67 positive cells. ImmunoperoxidaseDAB. Bar = 10 μm. Non neoplastic feline mammary gland with strong complete cell-membrane staining for HER-2/neu. IHC score: 3+ (D1). UH
displaying moderate complete membrane HER-2/neu expression in few cells. IHC score: 2+ (D2). ADH showing strong complete membrane
HER-2/neu expression. IHC score: 3+ (D3). Low-grade DCIS depicting strong complete membrane for HER-2/neu expression. IHC score: 3+ (D4).
Intermediate-grade DCIS showing moderate complete membrane HER-2/neu immunoreactivity. IHC score: 2+ (D5). High-grade DCIS showing
strong and complete membrane HER-2/neu staining. IHC score: 3+ (D6). Immunoperoxidase-DAB. Bar = 10 μm.

25.7 ± 2.1; median: 5; range: 1 - 90). Ductal hyperplasia
had significantly lower ER-a expression compared to
adjacent nonlesional gland (P = 0.005). Only 1 of the 15
ADH (7%) lesions had ER expression, which was of
moderate intensity and detected in 5% of the cells
(mean ± SD: 5 ± 1,15; median: 5; range: 3 - 5). No ER
expression was detected in DCIS. Of the 44 malignant

tumors examined, only 3 had weak to moderate ER
expression in 8% of the neoplastic cells (mean ± SD: 8 ±
1.28; median: 8; range: 8 - 12).
Expression of PR in IELs (Figure 3, B1-B6)

In 2 of 20 feline mammary non-neoplastic tissue (10%),
PR immunoreactivity was moderate in 17% of epithelial
cells (mean ± SD: 17 ± 2.23; median: 15.5; range: 14 - 26).
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Weak immunoreactivity was detected in 1 of 16 UH (6%)
in 5% of epithelial cells (mean ± SD: 5 ± 1.15; median: 4.5;
range: 4 - 7), 1 of 15 ADH (7%) in 2% of cells (mean ± SD:
2 ± 0.67; median: 2; range: 1 - 3) and 1 of 6 DCIS lowgrade (17%) in 2% of cells (mean ± SD: 2 ± 0.82; median:
2; range: 1 - 3). Expression of PR was not detected in the
intermediate or high-grade DCIS lesions or in examined
invasive mammary tumors.
Expression of Ki67 Nuclear Antigen in IELs (Figure 3, C1-C6)

Only a few normal epithelial cells had strong Ki67
expression (mean ± SD: 0.62 ± 1.06; median: 0.6; range:
0.3 - 1). Immunoreactivity for Ki67 correlated with the
IEL grade, with the strongest expression in high-grade
DCIS. There were significant differences among UH
(mean ± SD: 2.56 ± 1.68; median: 2; range: 1 - 10),
ADH (mean ± SD: 9.73 ± 2.14; median: 6; range: 1 - 25)
and DCIS (mean ± SD: 9.04 ± 1.62; median: 7.5; range:
2 - 26). Specifically, Ki67 expression was significantly
higher in ADH (p-value, 0.002) and DCIS (p-value,
0.002) than in UH. However, Ki67 did not differ significantly between ADH and DCIS (p-value, 0.7). Ki67
expression in IELs correlated with that in the adjacent
tumors. A regression model is fitted as Ki67 in tumors
(% value) = 0.038 + 0.609 * Ki67 in IEL (% value). This
regression model is significant with a p-value < 0.0001.
Similarly, Ki67 expression was increased in neoplasms
with higher histologic grade; however, the difference was
only significant between grade 3 tumors and adjacent
non-lesional gland (p-value < 0.05).
Expression of HER-2/Neu in IELs (Figure 3, D1-D6)

The expression pattern of HER-2/neu antigen was unexpected. Strong and complete membrane immunoreactivity was seen in greater than 10% of the epithelial cells in
non-lesional mammary gland adjacent to IELs or tumors
(scored 3+). Four of 16 UH (25%) and four of 15 ADH
(27%) were positive. Positive UH and ADH lesions were
scored 2+, except one ADH, which was scored 3+. In
DCIS, HER-2/neu was over-expressed in 9 of 28 cases
(32%); 7 DCIS were scored 2+ and 2 DCIS were scored
3+. All remaining IELs were negative (scored 0 or 1+).
Twelve of 44 neoplasms (27%) were positive; 10 tumors
were scored 2+ and 2 tumors were scored 3+.
SDS-PAGE and Western Immunoblotting

To investigate whether the IHC reactivity in nonlesional or lesional mammary tissue was due to a true
expression of HER-2/neu or to a non-specific reactivity
against other proteins, 5 normal feline mammary glands
and 5 malignant feline mammary tumors were subjected
to western immunoblotting. A 185-kDa band, corresponding to HER-2/neu, was observed in tumor samples
(Figure 4, lanes 1-2-3-4). The molecular weight corresponded to that described by the manufacturer of the
DAKO antibody and it was confirmed by the human
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Figure 4 Reactivity observed by western immunoblot with the
Dako Cytomation anti-HER-2/neu antibody in 4 feline
mammary tumors. Lanes 1-4: Feline mammary tumors; Lanes 5-8:
non-neoplastic feline mammary tissues; Lane 9: feline liver. The
molecular weight of the reactive protein band is indicated on the
right.

protein atlas for human HER-2/neu. Unexpectedly, a
band of corresponding molecular weight was also
observed in non-lesional mammary tissue samples (Figure 4, Lanes 6-7-8). However, differences in band intensity were observed at comparable total protein loads. In
particular, blotting of neoplastic tissues produced two
different types of band, either of weak (Figure 4, Lanes
1-2) or strong intensity (Figure 4, Lanes 3-4). Normal
mammary tissues had a clearly detectable band of intermediate intensity (Figure 4, Lanes 6-7-8). Only one sample was negative (Figure 4, Line 5); however, features of
degradation in the total protein pattern might explain
the negativity of that sample. Feline liver, used as a control, did not react with the same antibody (Figure 4,
Lane 9).

Discussion
Atypical lesions (ADH; DCIS) are predictors of invasive
breast cancer [3,4]. However, monitoring the progression and invasion of these lesions in humans is not
practical because the current standard therapy for DCIS
is complete excision [35]. Thus, establishing an animal
model for IELs that correlates with invasive mammary
carcinoma is important to develop preventive measures
and effective treatments as well as for understanding the
pathogenesis of the breast cancer.
Mammary IELs have not been well characterized in
genetically engineered mouse models [36], principally
because they are not spontaneous, but rather induced by
chemicals, radiation, or genetic modification. As in
humans, and in contrast to mice and rats, spontaneous
mammary tumors are quite common in cats [9,11].
Even though cats may not develop mammary neoplasia
as frequently as dogs, their tumors more closely resemble those in women. For example, the benign mixed
tumor that is so common in dogs almost never develops
in cats or women [37].
Although feline IELs (ductal hyperplasia and carcinoma in situ) have been reported, these lesions were
not described in detail or compared with human IELs.
Consequently, we evaluated mammary IELs and expression of ER, PR, and HER-2/neu in feline mastectomy
specimens. Ki67 proliferation index was also estimated.
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IELs were observed in 28% of mastectomy specimens
from female cats with clinical mammary disease; 79%
were associated with malignant neoplasms. DCIS was
the most common lesion, as in human mammary biopsy
specimens [26]; 89% of DCIS lesions were adjacent to
malignant tumors. ADH was detected less commonly
than DCIS; nevertheless, 95% of these lesions were adjacent to malignant tumors. In contrast, about 50% of UH
lesions were adjacent to benign tumors, duct ectasias or
fibroadenomatous change, consistent with its only
slightly elevated cancer risk in women [38]. In our
study, the prevalence of IELs in feline mammary gland
may have been underestimated because only minimal
peritumoral tissue was available for histologic evaluation.
Estrogen receptor expression in benign mammary
epithelium could be a risk factor for malignancy by rendering cells susceptible to the proliferative stimulus of
estrogens [39]. In this study, ER was expressed in 62.5%
of UH and in 7% of ADH, whereas all DCIS and 93% of
tumors were negative. These data confirm that some
feline mammary dysplasias and most neoplasms are
estrogen receptor-negative as reported by Martin de las
Mulas [20] and Millanta [40]. In cats, ER expression dramatically decreased as the IELs increased in grade; almost
all neoplasms were negative for this marker. Most preinvasive lesions were ER-negative. Allred suggested that
human ER-negative IELs could be involved in the development of ER-negative DCIS and its evolution into the
30% ER-negative human breast cancers [19].
PR immunoreactivity was low in non-lesional mammary gland, IELs, and tumors in contrast to the findings
of Millanta and de las Mulas [40,41]. This disparity may
be due to a different proportion of ovariectomized cats,
different stages of the estrus cycle, administration of
exogenous progestins, or different PR immunohistochemical technique. Positivity was observed in only 6%
of UH, in 7% of ADH, and in 17% of low-grade DCIS.
No immunoreactivity was detected in intermediategrade or high-grade DCIS, or in any of the 44 tumors.
As for ER, PR expression decreased with increasing
grade of IEL.
In agreement with Millanta and Dias Pereira [42,43],
the Ki67 proliferative index increased from normal
mammary tissue through IELs to malignant tumors. In
our study, the expression of Ki67 correlated with the
grade of malignant lesions and was inversely associated
with ER expression. In fact, highly proliferative lesions
tended to lose ER expression. In humans, Ki67 expression increased with increasing tumor grade and correlated with decreased overall survival rates and poor
response to hormonal therapy. In cats, use of Ki67 as a
prognostic factor for survival with mammary carcinoma
has produced conflicting results. Studies by Castagnaro
et al revealed an association between Ki-67 index and
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biological behavior [44]; however, Millanta et al
reported no significant prognostic importance in feline
mammary carcinomas [42]. In a recent investigation by
Dias Pereira, the Ki67 index correlated positively for
different histologic lesions and tumor types with
grade [43].
HER-2/neu IHC results were surprising and differed
from those of De Maria, Ordas, and Millanta [23-25].
Those authors reported no immunoreactivity [24,25], or
a faint, barely perceptible signal in part of the cell membrane [23] in normal mammary ducts and acini. A number of normal tissues, including breast, express this
receptor, which probably has a role in normal cell function, regulating growth and proliferation [45]. However,
we found HER-2/neu protein expression in normal
mammary epithelium with strong, complete membrane
staining (3+), contrary to what is observed in humans
[46]. Immunohistochemical HER-2 protein overexpression was found in 27% of IELs and in 27% of tumors.
HER-2/neu expression was confirmed by Western Blot,
in which both normal and neoplastic tissue showed a
185 kDa band, corresponding to human HER-2/neu.
Differences in signal intensity, however, were observed
at comparable total protein loads. This result could
reflect a higher expression of HER-2/neu in some neoplastic tissues, as in the case of samples corresponding
to lanes 3-4 of Figure 4, characterized by a stronger signal compared to neoplastic samples in lanes 1-2, and to
healthy tissues (lanes 5 to 8). However, the presence of
HER-2/neu signal in adjacent histologically normal tissues, although constantly observed throughout this
study, is unexpected, and needs explanation. If the
DAKO antibody cross-reacts with a physiological epidermal growth factor normally expressed in the feline
mammary gland, an increase in antibody specificity
could overcome this issue. If the polyclonal antibody
reacts with both HER-2/neu and another epidermal
growth factor receptor (EGFR) normally expressed in
ducts and acini of non neoplastic mammary feline tissue, that would explain the differences in signal intensity
both within neoplastic samples, and between neoplastic
and healthy tissue samples. Furthermore, the HER-2/neu
protein could be present at higher levels in the normal
feline mammary gland compared to the normal human
mammary gland. Further investigations will be necessary
to clarify the exact nature of this unexpected reactivity.
Similar to what was reported by Antuofermo in dogs,
about half the feline IELs without atypia (UH) were
associated with benign disease, whereas atypical IELs
(ADH and DCIS) were generally associated with mammary cancer [47]. The histologic grades of feline mammary carcinomas in our study were similar to those
reported by Castagnaro [31]. Like Seixas [34], we recognized cases of micropapillary carcinoma.
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Conclusions
In summary, mammary IELs develop spontaneously in
female cats, with high prevalence, and share the full
spectrum of morphologic features with human preinvasive breast lesions. The hypothetical multistep model of
breast carcinogenesis proposes that invasive carcinoma
arises via a series of intermediate hyperplastic lesions
through various grades of atypia to in situ and invasive
carcinoma. This implies that most ER-negative invasive
breast carcinomas probably evolved from ER-negative
DCIS, both of which represent about 25% of their
respective categories. Similarly, most DCIS probably
evolved from ADH, in which nearly all cells are highly
ER-positive. However, at least a few ER-negative cells
are present in all types of preinvasive lesions, including
ADH, and could be progenitor cells in the development
of ER-negative DCIS [19]. The loss of ER and PR
expression in most feline atypical IELs and carcinomas
supports the cat as a model for human ER- and PRnegative pre-invasive breast disease. New technology,
such as microdissection, DNA microarray, and proteomics, will help elucidate the factors involved in the
progression from IELs to invasive breast cancer.
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